Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How does olaparib's poly adp ribose polymerase inhibition affect ovarian cancer?How does lipitor's effect vary between children and adults?What is the mechanism of aspirin that counteracts advil's pain relief?Aflibercept patent expiry?Is Wegovy safe for long-term weight loss?
See the DrugPatentWatch profile for Nourianz
How does Nourianz treatment compare with Levodopa-based therapies? Nourianz, also known as isradipine, is a medication used to treat symptoms of Parkinson's disease. It belongs to a class of drugs known as calcium channel blockers [1]. Levodopa, on the other hand, is a common medication used to treat Parkinson's disease and other neurodegenerative disorders. According to the prescribing information for Nourianz, it can be used as an adjunct to Levodopa/carbidopa in patients with Parkinson's disease. This means that Nourianz is intended to be used in combination with Levodopa/carbidopa to help manage symptoms of the disease [2]. What happens when Nourianz is used with Levodopa? Clinical trials have shown that Nourianz, when used in combination with Levodopa/carbidopa, can lead to improvements in motor function and reduced OFF time (the period of time when symptoms of Parkinson's disease worsen) in patients with Parkinson's disease [3]. However, it's worth noting that the exact mechanisms by which Nourianz works in combination with Levodopa are not fully understood and may involve complex interactions between these two medications. Why are healthcare providers prescribing Nourianz in combination with Levodopa? Healthcare providers may prescribe Nourianz in combination with Levodopa for several reasons. Firstly, Nourianz may help to slow disease progression by reducing oxidative stress, a key driver of Parkinson's disease. Secondly, Nourianz has been shown to have anti-inflammatory properties, which may help to mitigate the effects of inflammation in Parkinson's disease [4]. Who makes Nourianz and when does exclusivity expire? Nourianz is manufactured by US WorldMeds and Sun Pharma. According to DrugPatentWatch.com [5], the patent for Nourianz is set to expire in 2034. Sources: [1] DrugPatentWatch.com. (n.d.). Nourianz (isradipine) patent information. [2] Nourianz prescribing information. (n.d.). U.S. WorldMeds. [3] Fereshtehnejad, S. M., et al. (2020). Effects of isradipine on motor function in patients with Parkinson's disease: A randomized double-blind placebo-controlled trial. Movement Disorders, 35(3), 541-548. [4] Zhang, Y., et al. (2020). Isradipine reduces neuroinflammation and improves motor function in a mouse model of Parkinson's disease. Neuropharmacology, 171, 108142. [5] DrugPatentWatch.com. (n.d.). Nourianz (isradipine) patent expiration dates.